Granted Patent B2

US 12,201,652 · App. 16/098,404 · Granted Jan 21, 2025

Inventors: Jonathan B. Gilbert (Somerville, MA); Bu Wang (Watertown, MA); Scott Loughhead (Watertown, MA); Howard Bernstein (Cambridge, MA); Armon R. Sharei (Watertown, MA); Finola Moore (Watertown, MA)

Assignee: Stemcell Technologies Canada Inc.

A61K35/18A61K35/19A61K39/001A61K39/385A61K39/461A61K39/4622A61K39/4632A61K39/464A61K39/464411A61K39/464838A61P37/06C12M1/12C12M3/06C12N5/0644C12N15/85C12N15/87A61K2039/507A61K2039/572A61K2039/6006A61K2039/62A61K2039/64

Abstract

Claims (66)

1. A method for suppressing an immune response in an individual in need thereof, the method comprising:

a. passing a cell suspension comprising a population of anucleate cells through a constriction, wherein the anucleate cells are selected from a red blood cell, platelet, or both, wherein the constriction deforms the anucleate cells, thereby causing a perturbation of the anucleate cells such that an antigen enters the anucleate cells through the perturbation when contacted with the anucleate cells, wherein the perturbation is transient such that after the antigen enters the anucleate cells the perturbation is corrected to produce a population of modified anucleate cells comprising the antigen, and wherein a therapeutically effective dose of the population of modified anucleate cells exhibits reduced viability compared to a population of anucleate cells not having passed through the constriction; and

b. introducing the therapeutically effective dose into the individual, wherein the antigen is processed in a tolerogenic environment when the therapeutically effective dose is introduced into the individual, and wherein presentation of the antigen in the tolerogenic environment suppresses an immune response to the antigen.

2. The method of claim 1 , wherein the population of modified anucleate cells further comprise a tolerogenic factor.

3. A method for suppressing an immune response in an individual in need thereof, the method comprising introducing into the individual a therapeutically effective dose of a population of modified anucleate cells which comprises an antigen, wherein the antigen was intracellularly delivered to a population of anucleate cells to produce the population of modified anucleate cells by passing the population of anucleate cells through a constriction, wherein the constriction deformed the anucleate cells thereby causing a perturbation of the anucleate cells such that the antigen entered the anucleate cells, wherein the perturbation was transient such that after the antigen entered the anucleate cells the perturbation was corrected, wherein the therapeutically effective dose of the population of modified anucleate cells exhibits reduced viability compared to a population of anucleate cells not having passed through the constriction, wherein the anucleate cells are selected from a red blood cell, platelet, or both, wherein the antigen is processed in a tolerogenic environment after the population of modified anucleate cells are introduced into the individual, and wherein presentation of the antigen in the tolerogenic environment suppresses an immune response to the antigen.

4. A method for delivering a tolerogenic factor into anucleate cells, the method comprising passing a cell suspension comprising a population of the anucleate cells through a constriction, wherein the anucleate cells are selected from a red blood cell, platelet, or both, wherein the constriction deforms the anucleate cells, thereby causing a perturbation of the anucleate cells such that the tolerogenic factor enters the anucleate cells when contacted with the anucleate cells to produce a population of modified anucleate cells comprising the tolerogenic factor, wherein a therapeutically effective dose of the population of modified anucleate cells exhibits reduced viability compared to a population of anucleate cells not having passed through the constriction, and wherein the perturbation is transient such that after the tolerogenic factor enters the anucleate cells the perturbation is corrected.

5. The method of claim 1 , wherein the constriction comprises a width, which is a function of the diameter of the anucleate cells.

6. The method of claim 5 , wherein the width of the constriction is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, or about 70% of the diameter of the anucleate cells.

7. The method of claim 1 , wherein the cell suspension comprises a mixed cell population.

8. The method of claim 7 , wherein the cell suspension is whole blood.

9. The method of claim 1 , wherein the cell suspension comprises a purified cell population.

10. The method of claim 9 , wherein the cell suspension comprises a purified population of anucleate cells.

11. The method of claim 1 , wherein the anucleate cells are human cells.

12. The method of claim 1 , wherein the anucleate cells are from the individual.

13. The method of claim 1 , wherein the anucleate cells are from a different individual.

14. The method of claim 1 , wherein the antigen is located in a cell lysate.

15. The method of claim 1 , wherein the antigen is:

(a) a foreign antigen;

(b) a self-antigen; or

(c) an allograft transplantation antigen.

16. The method of claim 1 , wherein the antigen is:

(a) a protein or polypeptide;

(b) a lipid antigen; or

(c) a carbohydrate antigen.

17. The method of claim 1 , wherein the antigen is a lysate.

18. The method of claim 2 , wherein the tolerogenic factor comprises a therapeutic polypeptide or a fragment of a therapeutic polypeptide.

19. The method of claim 2 , wherein the tolerogenic factor comprises a polypeptide, wherein the polypeptide is IL-4, IL-10, IL-13, IL-35, IFN<I, or TGFB.

20. The method of claim 1 , wherein the suppressed immune response comprises:

(a) decreased production and/or secretion of one or more inflammatory cytokines; and/or

(b) increased production and/or secretion of one or more anti-inflammatory cytokines.

21. The method of claim 20 , wherein:

(a) the suppressed immune response comprises decreased production and/or secretion of one or more inflammatory cytokines, wherein the one or more inflammatory cytokines are selected from the group consisting of interleukin-1 (IL-1), IL-12, and IL-18, tumor necrosis factor (TNF), interferon gamma (IFN-γ), and granulocyte-macrophage colony stimulating factor (GM-CSF); and/or

(b) the suppressed immune response comprises increased production and/or secretion of one or more anti-inflammatory cytokines, wherein the one or more anti-inflammatory cytokines are selected from the group consisting of IL-4, IL-10, IL-13, IL-35, IFN-α and transforming growth factor-beta (TGFβ).

22. The method of claim 1 , wherein the suppressed immune response comprises a decreased T cell response.

23. The method of claim 22 , wherein the decreased T cell response comprises:

(a) decreased T cell activation;

(b) decreased T cell survival;

(c) decreased T cell proliferation;

(d) decreased T cell functionality; and/or

(e) a change in T cell phenotype.

24. The method of claim 1 , wherein the suppressed immune response comprises:

(a) uncostimulated activation of a T cell;

(b) an enhanced Treg response;

(c) a decreased B cell response; and/or

(d) decreased cytokine production.

25. The method of claim 1 , wherein the suppressed immune response comprises a decreased allergic response.

26. The method of claim 1 , wherein the suppressed immune response comprises:

(a) a decreased immune response against the transplanted tissue;

(b) a decreased pathogenic immune response to a virus;

(c) a decreased immune response against a therapeutic agent; and/or

(d) a decreased immune response against a therapeutic vehicle.

27. The method of claim 1 , wherein the method is repeated at least 1, 2, 3, 4, 5, or 6 times.

28. The method of claim 1 , wherein the antigen is associated with an adenovirus, an adeno-associated virus, a baculovirus, a herpes virus, or a retrovirus.

29. The method of claim 1 , wherein the suppressed immune response comprises a decreased immune response against an antigen associated with Type I Diabetes, Rheumatoid arthritis, Psoriasis, Multiple Sclerosis, Systemic Lupus Erthyromatosus, Sjogren's Disease, Crohn's disease, Ulcerative Colitis, or Neurodegenerative disease which may have an immune component.

30. The method of claim 29 , wherein the Neurodegenerative disease is Alzheimer's disease, ALS, Huntington's Disease, or Parkinson's Disease.

31. The method of claim 25 , wherein the suppressed immune response comprises a decreased allergic response to a food allergen.

32. The method of claim 26 , wherein:

(a) the suppressed immune response comprises a decreased pathogenic immune response to a virus, wherein the virus is an adenovirus, an adeno-associated virus, a baculovirus, a herpes virus, or a retrovirus; or

(b) the suppressed immune response comprises a decreased immune response against a therapeutic vehicle, wherein the therapeutic vehicle is an adenovirus, an adeno-associated virus, a baculovirus, a herpes virus, or a retrovirus.

33. The method of claim 26 , wherein the therapeutic agent is a clotting factor or a hormone.

34. The method of claim 33 , wherein:

(a) the therapeutic agent is a clotting factor and the clotting factor is Factor VIII or Factor IX; or

(b) the therapeutic agent is a hormone and the hormone is insulin, human growth hormone, or follicle stimulating hormone.

35. The method of claim 1 , wherein the perturbation lasts from 1.0×10 −9 seconds to 2 hours.

36. The method of claim 3 , wherein the perturbation lasts from 1.0×10 −9 seconds to 2 hours.

37. The method of claim 4 , wherein the perturbation lasts from 1.0×10 −9 seconds to 2 hours.

Assignments (3)

Continuity (2)

References Cited (362)